The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11183195 | PMC |
| http://dx.doi.org/10.1002/imt2.202 | DOI Listing |
Publication Analysis
Top Keywords
pathobiome strains
12
live biotherapeutic
8
biotherapeutic products
8
feasibility pathobiome
4
strains live
4
products human
4
human evaluation
4
evaluation pathobiome
4
strains conducted
4
conducted strain
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!